ATC Group: L04AX Other immunosuppressants

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AX in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AX Other immunosuppressants

Group L04AX contents

Code Title
L04AX01 Azathioprine
L04AX02 Thalidomide
L04AX03 Methotrexate
L04AX04 Lenalidomide
L04AX05 Pirfenidone
L04AX06
L04AX07
L04AX08
L04AX09

Active ingredients in L04AX

Active Ingredient Description
Azathioprine

Azathioprine is a pro-drug of 6-mercaptopurine (6-MP). 6-MP is inactive but acts as a purine antagonist and requires cellular uptake and intracellular anabolism to thioguanine nucleotides (TGNs) for immunosuppression. The TGNs and other metabolites (e.g. 6-methyl-mecaptopurine ribonucleotides) inhibit de novo purine synthesis and purine nucleotide interconversions.

Darvadstrocel

Darvadstrocel contains expanded adipose stem cells (eASC), which exhibit immunomodulatory and anti-inflammatory effects at inflammation sites.

Dimethyl fumarate

The anti-inflammatory and immunomodulating effects of dimethyl fumarate and its metabolite monomethyl fumarate are not fully elucidated but are thought to be mainly due to the interaction with the intracellular reduced glutathione of cells directly involved in the pathogenesis of psoriasis. Their main activity is considered to be immunomodulatory, resulting in a shift in T helper cells (Th) from the Th1 and Th17 profile to a Th2 phenotype.

Lenalidomide

The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties.

Methotrexate

Methotrexate (4-amino-10-methylfolic acid) is a folic acid antagonist which inhibits the reduction of folic acid and increase of tissue cells. Methotrexate enters the cell through an active transport mechanism of reduced folates. As a result of polyglutamation of methotrexate caused by the folylpolyglutamylate enzyme, the duration of the cytotoxic effect of the drug substance in the cell increases.

Pirfenidone

Pirfenidone attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors. Pirfenidone is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).

Pomalidomide

Pomalidomide has direct anti-myeloma tumoricidal activity, immunomodulatory activities and inhibits stromal cell support for multiple myeloma tumour cell growth. Pomalidomide in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma.

Thalidomide

Thalidomide shows immunomodulatory, anti-inflammatory and potential anti-neoplastic activities. Thalidomide is also a non-barbiturate centrally active hypnotic sedative. It has no antibacterial effects.

Related product monographs

Title Information Source Document Type  
ALOFISEL Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
AZAMUN Film coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
AZATHIOPRINE / SANDOZ Film-coated tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
DIMETHYL FUMARATE MYLAN Gastro-resistant hard capsule European Medicines Agency (EU) MPI, EU: SmPC
ESBRIET Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
IMNOVID Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
IMUPRIN Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
IMURAN Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
JAYEMPI Oral suspension European Medicines Agency (EU) MPI, EU: SmPC
METHOFILL Solution for injection in pre-filled injector Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
METHOTREXATE Solution for Injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
METHOTREXATE Tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
METOJECT PEN Solution for injection in pre-filled pen Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
POMALYST Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
REVLIMID Capsules European Medicines Agency (EU) MPI, EU: SmPC
SKILARENCE Gastro-resistant tablet European Medicines Agency (EU) MPI, EU: SmPC
TECFIDERA Gastro-resistant hard capsule European Medicines Agency (EU) MPI, EU: SmPC
THALIDOMIDE CELGENE Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
THALOMID Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
VUMERITY Delayed-release capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
VUMERITY Gastro-resistant hard capsule European Medicines Agency (EU) MPI, EU: SmPC